TABLE 1.
Interventions in COVID‐19 dual combination pivotal clinical trials as of 29 March 2021. 15
| Intervention 1 | Intervention 2 | Trial ID | No. of subjects | Results |
|---|---|---|---|---|
| Bamlanivimab | Etesevimab | NCT04427501 | 3160 | Yes |
| Doxycycline | Ivermectin | NCT04729140 | 150 | No |
| Hydroxychloroquine | Azithromycin | NCT04336332 | 160 | No |
| Hydroxychloroquine | Azithromycin | NCT04344444 | 600 | No |
| Hydroxychloroquine | Baricitinib | NCT04373044 | 144 | No |
| Lopinavir/ritonavir | Favipiravir | NCT04499677 | 240 | No |
| Lopinavir/ritonavir | Favipiravir | 2020‐002106‐68 | 240 | No |
| Lopinavir/ritonavir | Hydroxychloroquine | NCT04386070 | 6400 | No |
| Melatonin | Toremifene | NCT04531748 | 390 | No |
| Methylene blue | Convalescent plasma | NCT04547127 | 200 | No |
| NA‐831 (Traneurocin) | Oral polio vaccine (OPV) | NCT04540185 | 3600 | No |
| Naltrexone | Colchicine | NCT04756128 | 164 | No |
| Oseltamivir | Vidofludimus calcium | NCT04516915 | 120 | No |
| Pamapimod | Pioglitazone | 2020‐005849‐16 | 144 | No |
| Remdesivir | Bamlanivimab | NCT04501978 | 10000 | Yes |
| Remdesivir | Baricitinib | NCT04401579 | 1034 | Yes |
| Remdesivir | Hyperimmune immunoglobulin | NCT04546581 | 593 | Yes |
| Remdesivir | Interferon beta‐1a | NCT04492475 | 969 | No |
| Remdesivir | Lenzilumab | NCT04583969 | 200 | No |
| Remdesivir | Risankizumab | NCT04583956 | 200 | No |
| Remdesivir | Tocilizumab | NCT04409262 | 649 | Yes |
| Rosuvastatin | Colchicine | NCT04472611 | 466 | No |
| Vitamin B‐ complex | Nitazoxanide | NCT04343248 | 800 | No |
| Vitamin B‐ complex | Nitazoxanide | NCT04359680 | 1407 | No |
| Vitamin B‐ complex | Nitazoxanide | NCT04486313 | 1092 | No |
| Vitamin D | Aspirin | NCT04363840 | 1080 | No |